Reply to: Kow CS et al. Are severe asthma patients at higher risk of developing severe outcomes from COVID-19?

Affiliations

• ¹ Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center IRCCS, Rozzano, Italy.
• ² Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
• ³ Department of Internal Medicine, Clinical Immunology, Clinical Pathology and Infectious Disease, Azienda Ospedaliera Universitaria Federico II, Napoli, Italy.
• ⁴ Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.
• ⁵ Department of Medical Sciences, AO Ordine Mauriziano Umberto I, University of Torino, Torino, Italy.
• ⁶ Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
• ⁷ Severe Asthma Network in Italy (SANI) infrastructure, Milano, Italy.
• ⁸ Allergy and Pneumology Unit, A.O. S. Croce e Carle, Cuneo, Italy.
• ⁹ Management Engineering Tourbillon Tech srl, Padova, Italy.
• ¹⁰ Respiratory Unit, Department of Health Sciences, ASST Santi Paolo e Carlo, San Paolo Hospital, University of Milano, Milano, Italy.
• ¹¹ Asthma Center and Allergy Unit, Verona University Hospital, Verona, Italy.
• ¹² Department of Surgery, Medicine, Molecular Biology and Critical Care, University of Pisa, Pisa, Italy.
• ¹³ Internal Medicine Department, Respiratory Unit and Adult Cystic Fibrosis Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy.
• ¹⁴ Department of Pathophysiology and Transplantation, University of Milano, Milano, Italy.